ENLV Financials: Enlivex Ltd AI Analysis



Financials

ENLV Financial

Enlivex Ltd

$0.88

-0.69%

$0

At close: Apr 27, 16:00:00 GMT-4

$0.89

1.96%

$0.01

Post-market: Apr 27, 20:00:00 GMT-4

Overview Forecast Earnings Dividends Financials

Key Stats

Prev.Close

$0.8885

Open

$0.88

Day's Range

$0.88 - $0.9099

52 week range

$0.66 - $2.1

Volume

274.4K

Avg.Volume

555.2K

Dividend yield

EPS (TTM)

-0.55

Market Cap

$213.5M

What is ENLV?

Enlivex Therapeutics Ltd. engages in the development of macrophage reprogramming immunotherapy products. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.

Features

Resources

Market

Income

Balance sheet

Cash flow

Annual

Quarterly

ENLV Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2025	09/30/2025	06/30/2025	03/31/2025	12/31/2024
Revenue	0	0	0	0	0	0
Revenue Growth (YoY)	--	--	--	--	--	--
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	--	--	--
Selling, General & Admin	5	2	1	0	0	2
Research & Development	9	3	1	2	2	3
Operating Expenses	14	5	2	3	3	5
Other Non Operating Income (Expenses)	--	363	--	--	0	--
Pretax Income	-12	1,625	-2	-1	-3	-5
Income Tax Expense	--	382	--	--	--	--
Net Income	-12	1,243	-2	-1	-3	-5
Net Income Growth	-33%	-24,960%	0%	-67%	-25%	-44%
Shares Outstanding (Diluted)	24.04	122.3	24.04	23.85	23.75	22.49
Shares Change (YoY)	13%	444%	13%	22%	27%	21%
EPS (Diluted)	-0.54	10.16	-0.09	-0.07	-0.14	-0.23
EPS Growth	-38%	-4,517%	-25%	-51%	-34%	-53%
Free Cash Flow	-11	-2	-1	-1	-4	-4
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	--	--	--	--	--	--
Operating Margin	0%	0%	0%	0%	0%	0%
Profit Margin	0%	0%	0%	0%	0%	0%
Free Cash Flow Margin	0%	0%	0%	0%	0%	0%
EBITDA	-14	-5	-2	-3	-3	-5
EBITDA Margin	0%	0%	0%	0%	0%	0%
D&A For EBITDA	0	0	0	0	0	0
EBIT	-14	-5	-2	-3	-3	-5
EBIT Margin	0%	0%	0%	0%	0%	0%
Effective Tax Rate	--	23.5%	--	--	--	--

Follow-Up Questions

What are Enlivex Ltd's key financial statements?



According to the latest financial statement (Form-10K), Enlivex Ltd has a total asset of $0, Net loss of $0

What are the key financial ratios for ENLV?



Enlivex Ltd's Current ratio is 0, has a Net margin is 0, sales per share of $0.

How is Enlivex Ltd's revenue broken down by segment or geography?



Enlivex Ltd largest revenue segment is Animal Health, at a revenue of 962,796,000 in the most earnings release.For geography, United States is the primary market for Enlivex Ltd, at a revenue of 739,919,000.

Is Enlivex Ltd profitable?



no, according to the latest financial statements, Enlivex Ltd has a net loss of $0

Does Enlivex Ltd have any liabilities?



no, Enlivex Ltd has liability of 0

How many outstanding shares for Enlivex Ltd?



Enlivex Ltd has a total outstanding shares of 0

Enlivex Ltd (ENLV) Financial

ENLV Stock Price Chart